ストックスクリーナーアプリを入手
141.69
2.27%
-3.29
アフターアワーズ：
142.50
0.81
+0.57%
前日終値:
$144.98
開ける：
$145.215
24時間の取引高:
1.42M
Relative Volume:
1.79
時価総額：
$6.85B
収益：
-
当期純損益:
$-177.04M
株価収益率:
-37.42
EPS:
-3.7867
ネットキャッシュフロー:
$-153.53M
1週間 パフォーマンス:
+18.01%
1か月 パフォーマンス:
+25.80%
6か月 パフォーマンス:
+89.96%
1年 パフォーマンス:
+1,206%
1日の値動き範囲:
$139.31
$147.33
1週間の範囲:
$116.50
$151.02
52週間の値動き範囲:
$9.51
$151.02
Celcuity Inc Stock (CELC) Company Profile
Compare CELC vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
141.69 | 7.01B | 0 | -177.04M | -153.53M | -3.7867 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-27 | 開始されました | Citizens | Mkt Outperform |
| 2025-12-12 | 開始されました | Wells Fargo | Overweight |
| 2025-11-18 | 開始されました | Wolfe Research | Outperform |
| 2025-11-17 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-09-22 | 開始されました | Guggenheim | Buy |
| 2025-07-01 | 再開されました | Stifel | Buy |
| 2024-07-22 | 開始されました | Leerink Partners | Outperform |
| 2024-02-22 | 開始されました | Stifel | Buy |
| 2023-12-08 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-08 | 開始されました | Canaccord Genuity | Buy |
| 2021-09-07 | 開始されました | Jefferies | Buy |
| 2021-07-29 | 開始されました | Cowen | Outperform |
| 2021-07-27 | 開始されました | Needham | Buy |
| 2021-01-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-11 | 再開されました | Craig Hallum | Buy |
| 2018-11-20 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Celcuity Inc (CELC) 最新ニュース
Is It Too Late To Consider Celcuity (CELC) After A 13x One Year Surge? - Yahoo Finance
ASCO 2026 preview – Celcuity gets a mutant coup | ApexOncoClinical Trials news and analysis - Oncology Pipeline
Celcuity reports Phase III VIKTORIA-1 trial results for breast cancer - Clinical Trials Arena
Celcuity’s gedatolisib beats Novartis drug in Phase III test - The Pharma Letter
CELC Stock Jumps As VIKTORIA-1 Trial Hits Key Goal - timothysykes.com
CELC Stock Jumps As VIKTORIA-1 Data Fuel FDA Push - StocksToTrade
Celcuity Stock Jumps 16% as Gedatolisib Breast-Cancer Data Raise FDA Stakes - TechStock²
CELC Stock Jumps As VIKTORIA-1 Phase 3 Data Impress Wall Street - timothysykes.com
Celcuity strengthens case for ASCO-spotlighted breast cancer drug - BioPharma Dive
Celcuity CELC Soars On Strong Phase 3 Cancer Data - StocksToTrade
Celcuity rises on gedatolisib on top-line data in breast cancer - BioWorld News
Celcuity shares jump 15.5% as Phase 3 VIKTORIA-1 topline results support potential label expansion path for gedatolisib - Quiver Quantitative
Wall Street believes Celcuity could become an acquisition target – why this analyst raised their price target by a whopping 76% - MSN
CELC Stock Surges As VIKTORIA-1 Trial Hits Phase 3 Milestone - timothysykes.com
Celcuity upgraded by H.C. Wainwright with a new price target - Quantisnow
Citizens raises Celcuity stock price target on Phase 3 trial win By Investing.com - Investing.com South Africa
Citizens raises Celcuity stock price target on Phase 3 trial win - Investing.com
Celcuity’s breast cancer win; Odyssey plans $205M IPO - Endpoints News
Needham raises Celcuity stock price target to $157 on trial data - Investing.com UK
Celcuity Stock Soars 14% to $143 on Positive Phase 3 Breast Cancer Trial Data - International Business Times Australia
Needham raises Celcuity stock price target to $157 on trial data By Investing.com - Investing.com South Africa
Guggenheim raises Celcuity stock price target on trial success By Investing.com - Investing.com Canada
Guggenheim raises Celcuity stock price target on trial success - Investing.com
Stifel raises Celcuity stock price target on trial data strength By Investing.com - Investing.com Australia
Celcuity upgraded to Buy from Neutral at H.C. Wainwright - TipRanks
Stifel raises Celcuity stock price target on trial data strength - Investing.com
Celcuity Shares Climb on Positive Breast-Cancer Drug Trial Results - marketscreener.com
Celcuity price target raised to $157 from $122 at Needham - TipRanks
This Airbnb Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
Wall Street Believes Celcuity Could Become An Acquisition Target – Why This Analyst Raised Their Price Target By A Whopping 76% - Stocktwits
Why Is Celcuity Stock Rallying Today? - Benzinga
As FDA decision nears, Celcuity posts win in PIK3CA-mutant breast cancer - FirstWord Pharma
Why Celcuity’s Hot Cancer Drug Stock Is Sinking - TipRanks
CELC stock jumps after hours on positive breast cancer trial data - MSN
Celcuity Stock Surges on Breakthrough Trial Results - TipRanks
Celcuity’s Gedatolisib Achieves Phase 3 Success in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer, Meeting Primary Endpoint in VIKTORIA-1 Trial 1 - Minichart
LifeSci Capital Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $165 - Moomoo
CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data - Stocktwits
Jennison Associates LLC Purchases Shares of 229,704 Celcuity, Inc. $CELC - MarketBeat
LifeSci Capital Maintains Celcuity(CELC.US) With Buy Rating, Raises Target Price to $165 - Moomoo
Celcuity Reports Positive Phase 3 Results for Gedatolisib - TipRanks
Why Celcuity Shares Are Dropping After Big Trial Win - TipRanks
Celcuity reports positive phase 3 trial results for gedatolisib By Investing.com - Investing.com Nigeria
Celcuity announced that its Phase III Viktoria-1 clinical trial has successfully achieved the primary endpoint in the Pik3CA mutant patient cohort. - Bitget
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort - The Manila Times
Celcuity reports positive phase 3 trial results for gedatolisib - Investing.com
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful ... - Caledonian Record
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary - GlobeNewswire
Biotech Stocks To Follow TodayMay 1st - MarketBeat
Celcuity (CELC) Is Up 6.9% After FDA Grants Priority Review For Gedatolisib And Debt FinancingHas The Bull Case Changed? - simplywall.st
CELC.O Technical Analysis & Stock Price Forecast - Intellectia AI
Celcuity Inc (CELC) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):